Cencora Reports Strong Q2 Earnings, Raises FY26 EPS Guidance, and Announces $1 Billion Share Repurchase
COR is trading near its 52-week low of $271 (14% above the low).
Summary
Cencora reported strong Q2 fiscal 2026 earnings, raised its full-year adjusted diluted EPS guidance, and announced a $1 billion share repurchase program.
Key Events · Earnings and Guidance · COR
-
Strong Q2 Fiscal 2026 Financial Performance
Revenue increased 3.8% year-over-year to $78.4 billion. Adjusted diluted EPS rose 7.5% to $4.75, while GAAP diluted EPS was $8.40, including a $1.1 billion gain related to the OneOncology acquisition.
-
Raised Fiscal Year 2026 Adjusted EPS Guidance
The company updated its adjusted diluted EPS guidance for fiscal year 2026 to a range of $17.65 to $17.90, up from the previous range of $17.45 to $17.75.
-
Announced $1 Billion Share Repurchase Program
Cencora expects to repurchase $1 billion in shares by the end of calendar 2026, indicating a significant capital return to shareholders.
-
Strategic Portfolio Adjustments
The company announced a definitive agreement for MWI Animal Health to merge with Covetrus and the acquisition of EyeSouth Partners' retina business.
Analysis · COR · Trade & Services
Cencora delivered robust second-quarter fiscal 2026 results, exceeding expectations with a 7.5% increase in adjusted diluted EPS and a 3.8% rise in revenue. The company's decision to raise its full-year adjusted diluted EPS guidance signals strong confidence in its operational performance and future outlook. Furthermore, the announcement of a $1 billion share repurchase program by the end of calendar 2026 demonstrates a significant commitment to returning capital to shareholders, which is a material capital allocation decision for a company of this size. The financial impact of the OneOncology acquisition, including a substantial remeasurement gain, also contributed to the strong GAAP EPS.
At the time of this filing, COR was trading at $309.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $59.5B. The 52-week trading range was $271.00 to $377.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.